AtriCure, Inc. (ATRC), a medical instrument manufacturer, announced fourth-quarter and full-year 2025 financial results and provided rosy guidance for 2026. Following the news, ATRC shares are up 6.16% at $35.00.
For the fourth quarter of 2025, AtriCure delivered adjusted net income of $2.75 million, compared with a net loss of $3.57 million in the prior year. On a per-share basis, adjusted net income was $0.06 compared to a net loss of $0.08 in the year ago quarter.
Net income was $1.76 million or $0.04 per share in Q4, 2025 compared to a loss of $15.57 million OR $0.33 per share in the year-ago period.
Adjusted EBITDA increased to $19.86 million from $12.69 million in the prior year.
Total Revenue in the fourth quarter increased to $140.50 million from $124.77 million a year ago.
For the full year, adjusted net loss narrowed to $5.45 million from $31.34 million in the prior year. On a per-share basis, adjusted net loss shrank to $0.11 from $0.67 a year ago.
Net loss for the full year narrowed to $11.45 million from $44.70 million in the prior year. On a per-share basis, net loss shrank to $0.24 from $0.95 a year ago.
Adjusted EBITDA increased to $61.77 million from $31.12 million in the prior year.
Total revenue for the full year increased to $534.53 million from $465.31 million a year ago, an increase of nearly 15%.
For the full year, US-based revenue improved to $435.37 million from $382.82 million in the prior year.
U.S. revenue growth was driven by sales of cryoSPHERE MAX probe for post-operative pain management, AtriClip FLEX-Mini device for appendage management and the EnCompass clamp in open ablation.
Looking ahead to 2026, the management projects full-year 2026 revenue of approximately $600 million to $610 million, reflecting growth of approximately 12% to 14% over full-year 2025.
Full year 2026 adjusted earnings per share are expected to be in the range of $0.09 to $0.15, and net earnings per share are expected to be in the range of $0.00 to $0.04.
The firm also projects full-year adjusted EBITDA of approximately $80 million to $82 million in 2026, with positive net income.
In addition, the management expects continued positive cash generation for 2026.
ATRC has traded between $28.29 and $43.18 in the last 1 year. The stock closed Tuesday's trade at $32.97,up 0.98%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.